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OBJECTIVES The purpose of this study was to determine the efficacy of implantable cardiac defibrillator
(ICD) therapy in preventing sudden cardiac death (SCD) in post-infarction patients with
advanced left ventricular (LV) dysfunction.
BACKGROUND The Multicenter Automatic Defibrillator Implantation Trial (MADIT-II) randomized 1,232
post-infarction patients with an ejection fraction of 30% to ICD or conventional therapy.
In the ICD group, there was a 31% decrease in the risk of total mortality. However, a better
understanding of the mode of death is desirable in order to refine therapeutic interventions
in high-risk populations.
METHODS We evaluated the 202 deaths, using a variation of the Hinkle-Thaler classification system as
well as a clinical classification system to determine the incidence of SCD and the incidence
of cardiac death due to progressive LV failure.
RESULTS The SCD rates were 10.0% in the conventional group and 3.8% in the ICD group (p 0.01).
The hazard ratio for the risk of SCD in the ICD group compared with the conventional
therapy group was 0.33 (95% confidence interval 0.20 to 0.53, p 0.0001). The ICD had no
meaningful effect on non-sudden death (p  0.32). The effect of defibrillator therapy in
reducing SCD was similar in subgroup analyses stratified according to relevant baseline
characteristics.
CONCLUSIONS The decrease in mortality with ICD therapy in MADIT-II is entirely due to a reduction in
SCD, with similar reductions in SCD in a spectrum of subgroups stratified according to
relevant baseline characteristics. (J Am Coll Cardiol 2004;43:1459–65) © 2004 by the
American College of Cardiology FoundationH
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Trevious randomized studies (1,2) have shown that the
urvival rate in high-risk patients with coronary artery
isease, ventricular dysfunction, and inducible ventricular
achycardia can be increased by an implantable cardiac
efibrillator (ICD). The Multicenter Automatic Defibrilla-
or Implantation Trial II (MADIT-II) (3) assessed the
alue of prophylactic ICD therapy in patients with a history
f myocardial infarction (MI) and an ejection fraction (EF)
f 0.30 without the requirement for spontaneous or
nducible ventricular arrhythmias. The primary end point
as total mortality. The study showed a 31% reduction in
he risk of mortality in the ICD group compared with
onventional medical therapy.
In most cases of sudden cardiac death (SCD), the
resence of a terminal malignant arrhythmia is not known,
ecause electrocardiographic (ECG) monitoring is rarely
vailable. The MADIT-II End Point Review Committee,
stablished before the start-up of the trial, reviewed all
ortality events utilizing a variation of the traditional
From the *Cardiology Division of the Department of Medicine, St. Luke’s
oosevelt Hospital Center and Columbia University College of Physicians and
urgeons, New York, New York; and the †Cardiology Unit, Department of
edicine, University of Rochester Medical Center, Rochester, New York. ‡Members
f the MADIT-II End Point Review Committee, chaired by Dr. Henry Greenberg.
his study was supported by a research grant from Guidant Corporation, St. Paul,
innesota, to the University of Rochester School of Medicine and Dentistry.
Manuscript received July 8, 2003; revised manuscript received November 7, 2003,cccepted November 13, 2003.inkle-Thaler clinical classification system (2,4,5) in order
o determine the mode of death in the two treatment arms
f the trial. This report provides detailed analyses of the
erminal events in MADIT-II, with additional insight into
he efficacy of ICD therapy in patients with advanced left
entricular (LV) dysfunction.
ETHODS
etails of the methods used in MADIT-II have been
resented previously (3). MADIT-II randomized 1,232
atients with previous MI and a left ventricular ejection
raction of 0.30 to either ICD or conventional medical
herapy in a 3:2 ratio. An End Point Review Committee
Drs. Greenberg and Case), whose members were indepen-
ent of all aspects of the trial, reviewed the accumulated
ata on all deaths in MADIT-II, including relevant por-
ions of the ambulance, emergency room, and medical
ecords of patients who died, with a concentrated focus on
he clinical details of the terminal event. The narratives
upplied by clinical coordinators at the enrolling sites
ncluded a description of the circumstances surrounding
ach patient’s death, statements of those present at the
erminal event, prodromal symptoms, medications, location
f death, and time to death after the onset of symptoms.
he coordinators sought specific information on acuteoronary symptoms, especially chest pain, in the 24-h
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Mortality Events in MADIT-II April 21, 2004:1459–65nterval preceding death. The committee was not blinded as
o treatment allocation. The committee did not review any
CD printouts recorded at the time of death, of which there
ere very few, so as to maintain a uniform clinical assess-
ent of the time to death.
ortality definitions. A modified Hinkle-Thaler system
as used to classify deaths. The original Hinkle-Thaler
lassification (4) of suspected arrhythmic cardiac death was
ased almost exclusively on a sudden, unexpected death with
r without immediately preceding symptoms, with 95% of
hose classified as a presumed arrhythmic event dead within
h of cardiac symptoms. The ECG evidence of a terminal
rrhythmia was not required. In the current analysis, we
Table 1. Clinical Characteristics by Outcome
(
A. Baseline Characteristics
Age (yrs)
Male gender
NYHA functional class†
I
II
III/IV
Treatment for hypertension
Diabetes
Coronary angioplasty
Coronary bypass graft surgery
Interval 6 months between most recent MI
and enrollment
BUN 25 mg/dl
Atrial fibrillation
QRS interval 0.12 s
Right bundle branch block
Left bundle branch block
Ejection fraction (%)
B. Cardiac Morbidity After Enrollment
Hospitalization for heart failure
MI
Coronary revascularization
*p 0.01 for comparison between alive and dead within each
class represents highest class during the three months before
continuous variables, presented as the mean value  SD.
Abbreviations and Acronyms
ECG  electrocardiographic
EF  ejection fraction
HF  heart failure
HR  hazard ratio
ICD  implantable cardiac defibrillator
LV  left ventricular
MADIT-II  Multicenter Automatic Defibrillator
Implantation Trial
MI  myocardial infarction
NYHA  New York Heart Association
SCD  sudden cardiac deathBUN  blood urea nitrogen; MI  myocardial infarction.ave further defined this category, which is classified here as
CD, and includes those who: 1) died suddenly and
nexpectedly within 1 h of cardiac symptoms in the absence
f progressive cardiac deterioration (this category includes
everal patients whose time course of death was prolonged
y unsuccessful resuscitative measures, as well as patients
ho died within 1 h of the onset of cardiac symptoms in the
etting of stable heart failure [HF]); 2) died unexpectedly in
ed during sleep; and 3) died unexpectedly within 24 h after
ast being seen alive. Three patients were found more than
4 h after having been last seen alive and were classified as
nknown cause of death.
Patients categorized as SCD were subclassified into those
ith and without symptoms of severe LV dysfunction (New
ork Heart Association [NYHA] functional class III
F). Other Hinkle-Thaler categories of death included
on-SCD, unclassified cardiac death, non-cardiac death,
nd unknown/unclassified cause of death when insufficient
nformation was available to make a reasonable decision as
o the cause of death. Non-SCD included patients who died
f progressive cardiac failure or patients who did not meet
he time criteria for sudden death. Progressive cardiac
ailure was defined as unstable, clinical progression of
eteriorating pump function in the setting of active therapy,
ost often in an intensive care setting. However, patients
ith advanced HF in whom death was not anticipated as
ventional Group Defibrillator Group
e
93)
Dead
(n  97)
Alive
(n  637)
Dead
(n  105)
10 68  10* 64  11 69  9*
84 84 82
* *
29 36 27
27 37 27
44 27 46
55 53 54
43 32 42
31 47 36
56 58 59
89 88 87
49* 25 51*
16* 8 12
59 49 57
8 9 7
27 19 28
5 23  6* 23  5 22  6*
41* 20 60*
15* 4 20*
6 5 6
ent arm. †New York Heart Association (NYHA) functional
ment. All characteristics are given as percentages except forCon
Aliv
n  3
64 
86
41
36
23
53
36
45
56
87
28
7
49
7
16
24 
15
4
4
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April 21, 2004:1459–65 Mortality Events in MADIT-IImminent were categorized as sudden death if their terminal
vent met the time criteria.
In addition, an alternative clinical classification of death
eveloped before the analysis was also utilized. In this
linical classification scheme, SCD (death with 1 h of
ymptom onset) was subcategorized as primary when there
ere no preceding symptoms, or as secondary when a
omplaint of chest pain occurred during the 1-h period of
ime before death. Marked ECG changes indicative of
ctive myocardial ischemia were not present in any of the
eviewed records. A new multiple cause category was cre-
ted, and it required the presence of several medical prob-
ems in which coronary heart disease contributed to, but was
ot the dominant feature of, the mortality event. A category
f death related to cardiac procedures was also included.
ata analysis. Analyses used version 3.0 of the MADIT-II
atabase, released on July 26, 2002. For categorical vari-
bles, the chi-square statistic was used to assess group
ifferences. For continuous variables, comparisons were
Table 2. Cause of Death by Treatment Group
A. Modified Hinkle-Thaler Scheme
Cause of death
Cardiac death
Sudden death
Without severe LV dysfunction
With severe LV dysfunction
Non-sudden death
Unclassified cardiac death
Total cardiac death
Non-cardiac/non-coronary death
Unknown/unclassified
Nominal death rates
Cardiac death rate
Sudden cardiac death rate
Non-sudden cardiac death rate
Total all-cause mortality
B. Clinical Classification Scheme
Cause of death
Cardiac death
Sudden death
Primary arrhythmia (without preceding symp
Secondary arrhythmia (with chest pain sympt
Primary mechanical
Cardiac procedure
Multiple causes
Non-cardiac/non-coronary death
Unknown/unclassified death
Nominal death rates
Cardiac death
Sudden cardiac death
Primary mechanical cardiac death
Total all-cause mortality
*p  0.01 when comparing the two treatment groups. Data
calculated from the total number of deaths in each treatment g
rates are calculated from the numbers of specified deaths per
conventional group and 742 in the defibrillator group), exprerformed using the t test for independent samples. Cumu- mative survival curves were determined by the Kaplan-Meier
ethod (6), with a statistical comparison of cumulative
ortality by the log-rank method. The Cox proportional
azards regression model (7) was used to calculate the risk
or SCD and non-SCD in the total population and in
ubgroups stratified by relevant baseline characteristics for
atients randomized to ICD versus conventional therapy.
ESULTS
linical characteristics by outcome in the two treatment
roups. The baseline characteristics of those who survived
nd those who died in the two treatment groups are
resented in Table 1A. In both groups, those who died were
lder and had more advanced HF, a lower EF, and poorer
enal function at enrollment than those who survived.
The cardiac morbidity that occurred after enrollment in
he two treatment arms among those who survived and
hose who died are presented in Table 1B. In both treat-
Conventional Group
(n  97)
Defibrillator Group
(n  105)
49 (51%) 28 (27%)*
34 18
15 10
21 (22%) 43 (41%)*
10 (10%) 8 (8%)
80 79
12 (12%) 22 (21%)
5 (5%) 4 (4%)
16.3% (80/490) 10.6%* (79/742)
10.0% (49/490) 3.8%* (28/742)
4.3% (21/490) 5.8% (43/742)
19.8% (97/490) 14.2* (105/742)
48 (49%) 24 (23%)*
41 22
7 2
19 (20%) 40 (38%)
1 1
3 (3%) 8 (8%)
12 (12%) 22 (21%)
14 (10%) 10 (10%)
14.5% (71/490) 9.8%* (73/742)
9.8% (48/490) 3.2%* (24/742)
3.9% (19/490) 5.4% (40/742)
19.8% (97/490) 14.2* (105/742)
sented as the percentage of sudden and non-sudden deaths
The nominal cardiac, sudden, and non-sudden cardiac death
er of randomized patients in each treatment arm (490 in the
s a percent.toms)
oms)
are pre
roup.
numb
essed aent arms, those who died had a higher frequency of
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Mortality Events in MADIT-II April 21, 2004:1459–65ospitalization for congestive HF and interim MI after
nrollment than those who survived.
ode of death. The mode of death by treatment group
lassified by the modified Hinkle-Thaler scheme is pre-
ented in Table 2A. Sudden cardiac death made up 51% (49
f 97 patients) of the total deaths in the conventional
herapy group, compared with 27% (28 of 105) of the total
eaths in the ICD group. Sudden death constituted 61%
49 of 80 patients) of the cardiac deaths in the conventional
herapy group, compared with 35% (28 of 79) in the ICD
roup (chi-square 12.4, p  0.001). The distribution of
udden, non-sudden, and unclassified deaths as a percentage
f the cardiac deaths in the two treatment groups is shown
n Figure 1. Similar findings were obtained when using the
linical classification system (Table 2B). Chest pain symp-
oms suggestive of active myocardial ischemia infrequently
receded sudden death in either treatment group. The two
ardiac procedure deaths were both related to coronary
rtery bypass graft surgery; there were no deaths related to
CD implantation.
The nominal (raw) death rates, calculated from the
umber of specified deaths per number of randomized
atients in each treatment arm, are given in Table 2. The
CD rate was 3.8 % in the ICD group and 10.0 % in the
onventional therapy group (p  0.01). There was no
ignificant difference in non-sudden death rates in the two
reatment arms.
Kaplan-Meier estimates of the effect of ICD on cumu-
ative SCD are presented in Figure 2A. There is an early
nd progressive separation of the probability of sudden
eath between the two arms of the trial. The hazard ratio
igure 1. Distribution of sudden cardiac death (SCD), non-sudden cardiac
eath (NSCD), and unclassified cardiac deaths in the conventional and
efibrillator therapy groups of MADIT-II, which randomized 490 patients
o the conventional group and 742 patients to the defibrillator group. A
otal of 80 cardiac deaths occurred in the conventional group and 79 in the
efibrillator group, with a cardiac death rate of 16.3% and 10.6%,
espectively. The overall size of the two pie graphs is roughly proportional
o the relative cardiac mortality rates in the two treatment groups. Sudden
ardiac death makes up 61% of the cardiac deaths in the conventional
herapy group and 35% in the defibrillator group, with reverse percentages
or NSCD. The unlabeled solid-black area of each graph represents the
ercentage of unclassified cardiac deaths in each group.HR) for SCD was 0.33 (95% confidence interval 0.20 to 5.53; p  0.0001) indicating a 67% reduction in the risk of
CD at any interval of time among patients in the defibril-
ator group compared with those in the conventional ther-
py group.
The Kaplan-Meier estimates for non-sudden death are
imilarly presented in Figure 2B. There is a slightly higher
on-SCD rate in the ICD group than in the conventionally
reated group, especially during the first year, but this
eparation in the two curves is not statistically significant (p
0.32).
The ICD to conventional therapy HRs for SCD, utiliz-
ng selected baseline characteristics (Table 1), were similar
or all relevant subgroups, with values in the range of 0.23 to
.44; there were no statistically significant interactions. That
s, all patient subgroups had an equivalent reduction in SCD
ith ICD therapy. Cox analyses for non-SCD revealed
Rs in the range of 1.0 for all relevant subgroups, a
nding indicating the absence of an ICD effect on non-
CD.
hronology of terminal event. The times from the onset
f the terminal event to cardiac death by treatment group
re shown in Table 3. This time course was recorded in 143
atients. A smaller percentage of patients died within 1 h (p
0.01) and within 24 h of symptom onset in the defibril-
ator group compared with the conventional therapy group.
his finding was also evident in the death rates when
ombining the 1-h interval with the dead-in-bed category,
r when combining the 24-h interval with all unwitnessed
eaths (both p  0.01). Nearly twice as many delayed
ardiac deaths (24 h) occurred in the ICD group.
ocation of cardiac death. Patient locations at the time of
ardiac death are shown in Table 4. The out-of-hospital/
mergency department cardiac death rates were higher in
he conventional therapy group than in the ICD group
9.6% vs. 3.8%, p  0.01). The ICD group had a slightly
igher rate of death occurring in an in-hospital/extended
are facility than did the conventional group.
dverse cardiac events in the week before cardiac death.
he respective frequencies of the following adverse events in
he week before SCD in the conventional (n  49) versus
CD (n  28) patients were 4% vs. 4% for syncope, 4% vs.
% for angina pectoris, 10% vs. 4% for MI, 10% vs. 25% for
entricular arrhythmia, and 16% vs. 43% for congestive HF.
he adverse events other than congestive HF were infre-
uent in both treatment groups, and in no instance were the
ifferences meaningful.
ISCUSSION
he major finding from this analysis of the mortality events
n MADIT-II is that the improvement in survival with ICD
herapy is entirely due to a reduction in SCD. The SCD
ate was reduced from 10.0% in the conventional therapy
roup to 3.8% in the ICD group, and this absolute reduc-
ion of 6.2% is higher than the total mortality reduction of
.6% (19.8% to 14.2%) reported in the primary publication
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April 21, 2004:1459–65 Mortality Events in MADIT-II3). The HR is 0.33 for SCD, and this value is meaningfully
ower than the HR of 0.69 for total mortality.
The Kaplan-Meier cumulative SCD curves for the two
reatment groups show an early and progressive separation
Fig. 2A), in contrast to the delayed divergence when total
ortality was used as the end point (3). The early separation
n the SCD curves is consistent with effective termination of
alignant ventricular arrhythmias beginning early after
CD implantation. The lack of early separation in the total
ortality curves (Fig. 2 in reference 3) may be explained by
igure 2. Kaplan-Meier estimates of the cumulative probability of sudden car
eceive an implantable cardioverter-defibrillator (ICD) or conventional medic
reatment groups was significant (nominal p 0.0001), with two-year SCD ra
he overall difference in mortality between the two treatment groups was not s
he ICD and CONV groups, respectively.he slightly higher non-SCD rate during the first year after Snrollment in the ICD group compared with the conven-
ionally treated group (Fig. 2B). We cannot determine
hether the ICD contributes to a slight increase in non-
CD during the first year, or whether the conventionally
reated group has an unusually low early non-sudden death
ate, possibly a reflection of intrinsic variability in naturally
ccurring non-sudden cardiac events. It should be empha-
ized that the difference in non-SCD rates between the two
reatment arms is not statistically significant (p  0.32).
There were no significant differences in the reduction of
eath (SCD) (A) and non-sudden cardiac death (B) in the groups assigned to
apy (CONV). For SCD, the overall difference in mortality between the two
4.9% and 12.1% in the ICD and CONV groups, respectively. For non-SCD,
ant (nominal p  0.32), with two-year non-SCD rates of 7.0% and 4.6% indiac d
al ther
tes of
ignificCD by ICD in subgroup analyses stratified according to age,
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Mortality Events in MADIT-II April 21, 2004:1459–65ender, NYHA functional class, EF, QRS interval, interval
ince the most recent MI, and beta-blocker use. We were not
ble to identify any patient subgroup that achieved significantly
ncreased or decreased ICD efficacy for the prevention of SCD.
It is important to consider the meaning of sudden death in
his report. Abrupt, unexpected death of an ambulatory patient
s usually assumed to be due to a malignant cardiac arrhythmia,
xcept for a small percentage of patients who experience a
atastrophic event such as dissecting aortic aneurysm, pulmo-
ary embolus, cerebral hemorrhage, myocardial rupture, or
ther sudden non-arrhythmic death. However, precise evi-
ence of an arrhythmic cause of sudden death remains elusive,
s ECG recordings at the time of a terminal event are
nfrequent. However, the current findings that the ICD
ignificantly reduces the rate of SCD provide strong support
hat a ventricular tachycardia/fibrillation mechanism is respon-
ible for the vast majority of SCDs as presently categorized.
able 3. Chronology of Cardiac Death by Treatment Group
Conventional
Group
(n  72)
Defibrillator
Group
(n  71)
itnessed death
Instantaneous (1 min) 13 7
1 min but 1 h 9 4
Subtotal  1 h 22 (31%) 11 (15%)*
1 h but 24 h 5 9
Subtotal 24 h 27 (38%) 20 (28%)
24 h 21 (29%) 40 (56%)*
nwitnessed death
Found dead in bed 15 6
Found dead, not in bed 9 5
Subtotal unwitnessed death 24 (33%) 11 (15%)
ominal death rates
1 h  dead in bed 7.6% (37/490) 2.3%* (17/742)
24 h  unwitnessed deaths 10.4% (51/490) 4.2%* (31/742)
p 0.01 when comparing the two treatment groups. The time course of the terminal
vent in patients who died of cardiac death according to the Hinkle-Thaler
lassification (see Table 2) was recorded in 143 patients: 72 patients in the
onventional group and 71 patients in the defibrillator group. Data are presented as
he numbers of deaths, with the 1-h, 24-h, and 24-h percentages calculated
rom the number of specified deaths divided by the number of cardiac deaths in each
reatment group. For nominal death rates, see Table 2.
able 4. Location of Sudden and Non-Sudden Cardiac Death
y Treatment Group
Conventional
Group
(n  70)
Defibrillator
Group
(n  71)
ut-of-hospital 47 23
mergency department 0 5
n-hospital 17 35
xtended care facility 5 7
nknown 1 1
ominal death rates
Out-of-hospital 
emergency department
9.6% (47/490) 3.8%* (28/742)
In-hospital or extended
care facility
4.5% (22/490) 5.7% (42/742)
p  0.01 when comparing defibrillator group versus conventional group. Cardiac
eaths include only sudden and non-sudden cardiac death by the Hinkle-Thaler
lassification (see Table 2). Values are numbers of deaths. For nominal death rates, seerable 2.The percentage of patients categorized as dying of SCD
n the conventionally treated group was 61%, a value very
imilar to the 63% found in the recent national report from
he Center for Disease Control (8). Although SCD was
ignificantly reduced in MADIT-II by ICD, 35% of the
ardiac deaths that occurred in the ICD group were classi-
ed as SCD (Table 3). This important residual SCD rate
ay reflect the absence of an ICD-reversible ventricular
rrhythmia, a depressed or ischemic myocardial state that
annot withstand the physiologic challenge of a malignant
rrhythmia, a non-arrhythmic catastrophic event, ICD mal-
unction, or a combination of more than one of these
actors. The recent report by Mitchell et al. (9) provides
seful information in this regard. The mode of death was
nvestigated in over 300 ICD-treated patients by post-
ortem ICD interrogation. The mean EF for the group was
.27. Of 68 cardiac deaths categorized as sudden, 29% had
ost-shock electro-mechanical dissociation, 25% had ven-
ricular tachycardia/fibrillation uncorrected by shock, 16%
ad primary electro-mechanical dissociation, 13% had in-
essant ventricular tachyarrhythmias, and 16% had other
auses of their terminal event.
We and others have used the Hinkle-Thaler approach for
lassifying SCDs subcategorized by the degree of LV dysfunc-
ion (1,2,5). In our study, a reduction in SCD provided
mportant insight into the mechanism of ICD efficacy. How-
ver, there are problems with the application of the Hinkle-
haler schema to current ICD trials. Foremost among these is
he inability of the Hinkle-Thaler classification to categorize
otential mechanisms of death that are amenable to reversion
y an ICD. The Hinkle-Thaler schema directs attention
xclusively to the terminal event. Such a focus does not provide
nformation on those who may and may not have benefited
rom ICD therapy. For example, signs and symptoms of HF
hat often precede death by weeks to months may provide
mportant information on the factors contributing to the
erminal event and whether the patient is likely to benefit from
ppropriate ICD therapy, but this information is not utilized in
he Hinkle-Thaler approach. We attempted to improve on the
inkle-Thaler approach with our clinical classification
chema, and there was some improvement (Table 2), but
inimally so.
This analysis reinforces the assumption that the ICD
educes arrhythmic death in high-risk coronary patients,
espite a lack of certainty in individual cases. It is also clear
hat a clinical algorithm, such as the Hinkle-Thaler schema,
hich looks at the terminal event of such patients, permits
better insight into the mechanisms of death than does
otal mortality. It is also clear that neither the Hinkle-
haler nor the clinical algorithms used in this study attain a
recision that reflects the potential benefit of ICD, in that
either schema is able to identify subpopulations of patients
ho will not benefit from ICD therapy. In the future, the
linical classification of cardiac death in ICD trials should
e integrated with information obtained about the terminal
hythm from post-mortem ICD interrogation in order to
b
a
h
t
e
f
r
n
s
R
D
1
E
R
1
1465JACC Vol. 43, No. 8, 2004 Greenberg et al.
April 21, 2004:1459–65 Mortality Events in MADIT-IIetter identify the mechanism of the terminal cardiac event
nd the true potential of ICD to prevent SCD (9), again
elping to identify patients who may not benefit from ICD
herapy. The burden of positive expectation, the monetary
xpenditure associated with ICD therapy, and the recent
unctional improvement seen with biventricular pacing (10)
equire greater clarity in our understanding of the mecha-
isms of cardiac death, both arrhythmic death and progres-
ive HF death in at-risk populations.
eprint requests and correspondence: Dr. Henry Greenberg,
ivision of Cardiology, St. Luke’s Roosevelt Hospital Center,
000 10th Avenue, Room 3B-30, New York, New York 10019.
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